Ascendiant analyst Edward Woo maintained a Buy rating on BioSig Technologies (BSGM – Research Report) on April 4 and set a price target of $5.25. The company’s shares closed yesterday at $1.07.
According to TipRanks, Woo is an analyst with an average return of -1.7% and a 41.36% success rate. Woo covers the Healthcare sector, focusing on stocks such as BioSig Technologies, Vivos Therapeutics, and Biolase.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioSig Technologies with a $5.25 average price target.
See today’s best-performing stocks on TipRanks >>
BSGM market cap is currently $72.87M and has a P/E ratio of -1.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioSig Technologies, Inc. is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market. Its first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. Its ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.
Read More on BSGM:
- BioSig Announces New Advisory Board Member Edwin Wang
- BioSig Technologies announces new advisory board member Edwin Wang
- BioSig Technologies appoints Lorraine Spurge to Advisory Board
- BioSig Announces New Advisory Board Member Lorraine Spurge
- BioSig Technologies confirms no exposure to Silicon Valley Bank
